Cerebrolysin vs Semax: evidence, cost, and legality

Which is better, cerebrolysin or Semax?

Cerebrolysin is graded human RCT: CASTA randomized 1,070 acute stroke patients (no difference on the primary endpoint), CARS found better arm function after stroke rehabilitation in 208 patients, and Cochrane reviews rate the evidence low certainty. Semax is graded human observational, with no blinded placebo controlled trial. Cerebrolysin is also registered in many more countries. The win is on evidence, not access: in the United States Cerebrolysin cannot lawfully be obtained, while semax has a pending compounding path. [1] [2] [3] [4] [5] [6]

How do cerebrolysin and Semax compare?

Cerebrolysin and Semax compared by dimension
Dimension	CerebrolysinFavored	Semax
What it is [3] [7]	Enzymatically digested porcine brain extract: an undefined mixture of low molecular weight peptides and free amino acids.	A single defined synthetic heptapeptide, an analog of ACTH fragment 4-10.
Evidence grade [3] [4] [8] [9]	Human RCT: multiple randomized placebo controlled trials and Cochrane reviews, mostly industry supported.	Human observational: open comparative Russian studies without blinding or placebo.
Acute stroke results [1] [3] [4]	CASTA (1,070 patients): no difference on the 90 day combined endpoint; Cochrane 2020 (1,601 patients): no difference in death and a possible increase in non-fatal serious adverse events (RR 2.15).	Open studies reported faster regression of neurological deficit and better EEG measures when added to standard care.
Stroke rehabilitation and dementia [2] [8] [10] [11]	CARS (208 patients): better Action Research Arm Test scores at day 90. Alzheimer meta-analysis: small cognitive benefit at 4 weeks, not significant at 6 months. Vascular dementia: small benefit, very low certainty.	Fewer exacerbations reported in chronic cerebrovascular insufficiency; no dementia trials in indexed English literature.
Route and regimen in the literature [1] [2] [4]	Intravenous infusion, typically 30 mL daily for 10 to 21 days after stroke; given in a clinic.	Intranasal drops, 12 to 18 mg per day for 5 to 10 days in acute stroke; lower doses for cognitive uses.
Safety [3] [4] [12]	Possible increase in non-fatal serious adverse events in acute stroke; dizziness, headache, and agitation in dementia trials at placebo like rates.	Nasal irritation; anxiety, irritability, or insomnia reported anecdotally; no systematic blinded safety data.
FDA and US access [5] [6]	Never submitted to FDA. As an undefined animal derived mixture it is not eligible for 503A or 503B compounding, and personal importation is not lawful for routine use.	Removed from 503A Category 2 on April 15, 2026; PCAC recommended the 503A bulks list in July 2026; no final rule yet.
WADA status [13]	Not prohibited.	Not named on the WADA Prohibited List; whether it falls under S0 (non-approved substances) is unclear, so tested athletes should confirm with their anti-doping organization.

Evidence grade and regulatory status

Pulled from each peptide’s own record, so it stays in step with the peptide pages.

Cerebrolysin and Semax: grade, status, and cost
Attribute	Cerebrolysin	Semax
Class	Enzymatically digested porcine brain extract: a mixture of low molecular weight peptides (under 10 kDa) and free amino acids given by intravenous or intramuscular injection	Synthetic heptapeptide analog of ACTH fragment 4-10 (Met-Glu-His-Phe-Pro-Gly-Pro), a melanocortin derived nootropic and neuroprotective peptide
What it is	Porcine brain peptide mixture with several RCTs in stroke and dementia, mixed and low certainty results, approved in some countries but not by FDA.	Nasal peptide registered in Russia; rodent brain growth factor data and open label Russian stroke trials; not FDA approved; recommended for compounding in 2026.
Evidence	Evidence: Human RCT evidence	Evidence: Human observational evidence
FDA status	Regulatory: Unscheduled	Regulatory: Under FDA review
Compounding	Cerebrolysin has never been submitted to or reviewed by FDA and is not an FDA approved drug. As an undefined biological mixture derived from animal brain it is not a bulk drug substance eligible for 503A or 503B compounding, and it has not been nominated to the 503A bulks list. It is a registered prescription drug in Austria (where it is manufactured), Russia, China, South Korea, and many other countries. Importing it for personal use in the United States is not lawful under FDA rules except in narrow circumstances that do not apply to routine use.	Semax was placed on the FDA 503A Category 2 list (substances with significant safety risks) in 2023 and removed from it on April 15, 2026. On July 23 to 24, 2026 the Pharmacy Compounding Advisory Committee recommended adding semax to the 503A bulks list. As of the last verification date FDA has not published a final rule, so compounding pharmacies and state boards vary in whether they will fill it. It is not an FDA approved drug and is not eligible for 503B outsourcing. It is a registered prescription drug in Russia.
WADA	WADA: Not WADA prohibited	WADA: WADA status unclear
Routes	Intravenous infusion (all major trials), Intramuscular injection (approved labeling in some countries for smaller volumes)	Intranasal drops (Russian product and most sold forms), Subcutaneous injection (as sold, no published human data)
Typical cost	Not available through licensed channels in the United States. In countries where it is approved, pharmacy prices are roughly 30 to 80 USD per 10 mL ampoule, so a 10 to 20 day course of 30 mL daily costs roughly 900 to 4,800 USD in drug alone. Prices noted on the last verified date and vary by country.	No lawful compounded price: Semax is not on the 503A bulks list, and PCAC's July 2026 recommendation is advisory until FDA publishes a final rule. Advertised clinic prices are not a comparable price. Products sold as research chemicals are not lawful for human use and are not verified for identity or purity.
Last verified	Sep 27, 2026	Sep 22, 2026

Has cerebrolysin been tested directly against Semax?

No published trial has compared cerebrolysin and Semax directly. The dimensions above come from separate studies and labels, and cross-trial comparisons are less reliable than a direct trial.

What do cerebrolysin and Semax cost?

Typical cost of Cerebrolysin and Semax
Dimension	Cerebrolysin	Semax
Typical cost	Not available through licensed channels in the United States. In countries where it is approved, pharmacy prices are roughly 30 to 80 USD per 10 mL ampoule, so a 10 to 20 day course of 30 mL daily costs roughly 900 to 4,800 USD in drug alone. Prices noted on the last verified date and vary by country.	No lawful compounded price: Semax is not on the 503A bulks list, and PCAC's July 2026 recommendation is advisory until FDA publishes a final rule. Advertised clinic prices are not a comparable price. Products sold as research chemicals are not lawful for human use and are not verified for identity or purity.
Price detail	Price index in progress	Semax price by channel

Where a price index exists, the range is the cash price per month across branded, compounded, and telehealth channels, without insurance. The cost pages give each channel separately with its sources. Otherwise the typical cost from the peptide record is shown. Legal access depends on your state: see peptide legality by state.

Frequently asked questions

Does Cerebrolysin work for stroke?

The best evidence says the benefit is uncertain. The largest trial, CASTA with 1,070 patients, found no difference on its primary endpoint at 90 days, and the 2020 Cochrane review found no difference in death with a possible increase in non-fatal serious adverse events. A smaller rehabilitation trial, CARS, did find better arm function. [1] [2] [3]

Is semax better studied than Cerebrolysin?

No. Semax has only open label Russian studies without placebo control, while Cerebrolysin has several randomized placebo controlled trials and Cochrane reviews, even though those reviews rate the certainty as low. [3] [4] [8]

Can I get Cerebrolysin in the United States?

Not lawfully for routine use. It has never been submitted to FDA, it cannot be compounded because it is an undefined animal derived mixture, and personal importation does not meet FDA's narrow exceptions. It is a prescription drug in Austria, Russia, China, and other countries. [5]

Can I get semax in the United States?

Not from bulk today. Semax came off FDA Category 2 on April 15, 2026 and PCAC recommended it for the 503A bulks list in July 2026, but the recommendation is advisory: until FDA publishes a final rule it is not on the bulks list, a 503A pharmacy has no federal basis to compound it from bulk, and state boards cannot authorize what federal law does not. [5] [6]

Is Cerebrolysin helpful for Alzheimer disease?

Only modestly, if at all. An industry linked meta-analysis found a small cognitive benefit at 4 weeks that was not significant at 6 months, and a dose ranging trial found only the lowest dose improved cognition at 24 weeks. [10] [12]

Conditions studied

Sources

Numbered citations above point to these primary sources. PubMed entries link to the indexed abstract.

Cite this page

Free to cite and quote with a link. Data is licensed CC BY 4.0 with attribution to PeptideAgent.

APA style: PeptideAgent. (2026, September 22). Cerebrolysin vs Semax: evidence, cost, and legality. https://peptideagent.ai/compare/cerebrolysin-vs-semax
HTML link: <a href="https://peptideagent.ai/compare/cerebrolysin-vs-semax">Cerebrolysin vs Semax: evidence, cost, and legality</a>, PeptideAgent, updated September 22, 2026.

Cerebrolysin vs Semax

The short answer